The Skinny on Obesity Products

The total obesity products market, including drugs and device, is projected to reach more than $1.6 billion by 2010, growing at a compound annual rate of 36.1%. Success in this arena will depend on whether emerging drugs and devices can live up their hype and deliver the results needed to achieve regulatory approval and marketplace acceptance.

If there was ever a market that has all the makings to achieve blockbuster status, the obesity products market is it. According to the 2003-2004 National Health and Nutrition Examination Survey (NHANES), an estimated 66.2% of U.S. adults age 20 and older are now classified as "overweight or obese." This translates into more than 127 million overweight adults, 66 million obese adults, and 9 million morbidly obese adults in the U.S. alone. At the same time, the incidence of obesity is growing exponentially, at a rate that outpaces the growth of the total U.S. population. Each year an estimated 3.5 million people in the U.S. are newly classified as overweight or obese. And, despite increasing health awareness campaigns and attempts to slow down the obesity rate, the Centers for Disease Control and Prevention predict that the number of obese adults in the U.S. will more than double in the next five years, reaching an estimated 168 million by the year 2012 (Figure 1). Although the U.S. currently has the largest obese population in the world, the prevalence of obesity is increasing in other industrialized nations as well, affecting an estimated 300 million people worldwide.

A major driving force in the obesity products market is the need to stem the staggering costs of this disease. In addition to the human costs, the economic impact of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Execs On The Move: 12-23 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.